TY - JOUR
T1 - Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders
AU - Lebrun, Christine
AU - Cohen, Mikael
AU - Pignolet, Beatrice
AU - Seitz-Polski, Barbara
AU - Bucciarelli, Florence
AU - Benzaken, Sylvia
AU - Kantarci, Orhun
AU - Siva, Aksel
AU - Okuda, Darin
AU - Pelletier, Daniel
AU - Brassat, David
N1 - Funding Information:
F Bucchiarrelli and B Pignolet received a grant from NCT00942214 and NCT01981161
Funding Information:
BIONAT is funded by the French Ministry of Health (Projet Hospitalier de Recherche Clinique, PHRC 2008 ) the French MS Society (ARSEP 2007 , 2008 , 2010 ) and an FP7 Health Innovation 1 grant ( 2012 ).
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/9/15
Y1 - 2016/9/15
N2 - Background Radiologically isolated syndrome (RIS) is a sub clinical demyelinating neurological disorder and to date no biomarker that triggers the seminal event has been identified. As for multiple sclerosis (MS), disease activity and clinical course are unpredictable. In MS, exploratory studies reported increased IL-17 levels in CSF but results in detecting IL-17 in serum at different stage of the disease are controversial. Objectives We investigate levels of IL-17 in serum and CSF in patients diagnosed at different stages of demyelinating diseases (RIS, CIS, relapsing remitting (RR) or active multiple sclerosis patients:AMS) as a marker of inflammatory condition. Methods 1417 sera has been tested for IL-17A (1177 from active MS, 80 RRMS, 35 RIS, 35 CIS, 10 IIH: idiopathic intracranial hypertension, and 80 controls) and 240 CSF from RIS, CIS, IIH and controls. Results No difference has been found between RIS who early clinically converted and CIS patients who rapidly evolve in McDonald or clinically definite MS, nor active MS. No correlation was found with usual MRI or CSF criteria. Conclusion Our results do not confirm that IL-17 can be considerate as a reliable marker of inflammation in the demyelinating spectrum disorders, either in blood or CSF.
AB - Background Radiologically isolated syndrome (RIS) is a sub clinical demyelinating neurological disorder and to date no biomarker that triggers the seminal event has been identified. As for multiple sclerosis (MS), disease activity and clinical course are unpredictable. In MS, exploratory studies reported increased IL-17 levels in CSF but results in detecting IL-17 in serum at different stage of the disease are controversial. Objectives We investigate levels of IL-17 in serum and CSF in patients diagnosed at different stages of demyelinating diseases (RIS, CIS, relapsing remitting (RR) or active multiple sclerosis patients:AMS) as a marker of inflammatory condition. Methods 1417 sera has been tested for IL-17A (1177 from active MS, 80 RRMS, 35 RIS, 35 CIS, 10 IIH: idiopathic intracranial hypertension, and 80 controls) and 240 CSF from RIS, CIS, IIH and controls. Results No difference has been found between RIS who early clinically converted and CIS patients who rapidly evolve in McDonald or clinically definite MS, nor active MS. No correlation was found with usual MRI or CSF criteria. Conclusion Our results do not confirm that IL-17 can be considerate as a reliable marker of inflammation in the demyelinating spectrum disorders, either in blood or CSF.
KW - Biomarkers
KW - Clinically isolated syndrome
KW - Interleukin
KW - Multiple sclerosis
KW - Radiologically isolated syndrome
UR - http://www.scopus.com/inward/record.url?scp=84979632802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979632802&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2016.07.052
DO - 10.1016/j.jns.2016.07.052
M3 - Article
C2 - 27538659
AN - SCOPUS:84979632802
SN - 0022-510X
VL - 368
SP - 334
EP - 336
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
ER -